Rick H. Morton
Little Milton,Oxfordshire
Summary
Senior biopharmaceutical executive with 25+ years of global leadership experience spanning medical affairs, market access, value-based clinical development, health economics, and commercialization strategy across biotech, specialty pharma, and consulting organizations. Proven record of shaping pipeline and asset strategy from early development through launch, building global and regional functions, guiding portfolio investment decisions, developing medical affairs strategies, engagement an deliverables, and securing payer and HTA success across major markets. Deep experience advising biotech leadership teams and boards on value creation, commercialization readiness, and investor strategy. Recognized experience in ophthalmology, rare disease, neuroscience, immunology, oncology, specialty care, and advanced therapies, with extensive experience across EU, US, and Asia-Pacific markets. Trusted advisor to executive teams and boards; experienced in building high-performance global teams and establishing scalable operating models for emerging and mid-sized biotech organizations. Senior Biopharmaceutical Executive with extensive global leadership experience in medical affairs, market access, and commercialization strategy. Shaped pipeline and asset strategies from development through launch, driving engagement with payers and HTA for major markets. Built high-performance global teams and established scalable operating models for biotech organisations. Productive employee with proven track record of successful project management and producing quality outcomes through leadership and team motivation. Works with clients to determine requirements and provide excellent service.
Overview
22
22
years of professional experience
Work History
Head of Europe, Value Access & HTA
Neurocrine Biosciences
01.2023 - Current
- Executive lead establishing European value and access strategy to support commercialization of in market and late-stage and pipeline assets in neurology and rare diseases.
- Built European operating model supporting future asset launches.
- Integrated medical, HEOR, payer and HTA evidence requirements into clinical development.
- Led early access and scientific advice engagement with European authorities.
- Engagement with KOLs for strategic clinical development.
- Supporting establishment of EU commercial infrastructure and leadership hiring.
- Leading launch preparation strategy for congenital adrenal hyperplasia (CAH) asset.
- Evaluation of pipeline assets across a range of orphan diseases, neuroscience, and immunology.
Chairman of the Board
Biotherapy Services Ltd
01.2023 - Current
- Board leadership for regenerative medicine biotech supporting strategic planning, fundraising, and governance modernization during scale-up phase.
Chief Medical Affairs Officer & Global Head, WG Access
WPP Health / VMLY&R / WG Access
01.2018 - 01.2023
- Established and led global medical and value consulting organization delivering strategic advisory services to biotech and pharmaceutical clients.
- Built global function operating across US, EU, and Asia.
- Supported biotech companies in early insights from clinical and payer leaders to support asset positioning and development strategy.
- Delivered cross-functional alignment programs across development, medical affairs commercial, and access teams.
- Led medical and payer evidence strategy for multiple rare disease and oncology assets.
- Established global patient engagement initiatives.
- Provided internal strategic leadership across WPP healthcare network.
International Head, Value & Access
Allergan International (now AbbVie)
01.2013 - 01.2018
- Held successive executive leadership roles: Associate VP, International Pricing & Market Access, Head of HEOR, Pricing & Access – EMEA.
- Executive leadership roles overseeing global and regional value & access strategy across multiple therapeutic areas in particular Opthalmology (retinal disease and glaucoma, dry-eye disease).
- Executive member of global leadership decision bodies supporting ophthalmology pipeline and acquisition decisions.
- Led global value strategy for multiple specialty assets including Ophthalmology.
- Managed international access strategy across 20+ markets.
- Supported integration strategy for acquisitions.
- Mentored senior commercial and R&D talent.
Global Director, Market Access
Novartis Pharma
01.2012 - 12.2012
- Led global value evidence strategy integrating clinical, economic, and payer requirements into asset development programs.
- Basel
Vice President & Senior Director, Consulting
PAREXEL International
01.2009 - 12.2012
- Led clinical and commercial consulting practice advising pharma and biotech companies on global development and commercialization strategy.
Managing Director
WG Consulting (WPP)
01.2004 - 12.2009
- Built and led global medical affairs and market access consultancy supporting pharmaceutical companies across major markets and therapeutic areas.
Education
PhD - Neuropharmacology
University of Manchester
BSc (Hons) - Pharmacology
University of Liverpool
Strategic Leadership Programme -
Chicago Booth School of Business
Health Economics Certificate -
Brunel University
TEFL -
Florence
Skills
- Enterprise & asset value strategy
- Global market access & pricing leadership
- Medical affairs & evidence strategy
- Health economics & outcomes research (HEOR)
- Early development value optimization
- HTA & payer evidence strategy
- Launch readiness & commercialization planning
- Cross-functional R&D alignment
- Portfolio & indication sequencing
- Investor and board engagement
- Global function build & transformation
- M&A and integration support
Languages
English
Italian
Custom Section
Senior biopharmaceutical executive with 25+ years of global leadership experience spanning medical affairs, market access, value-based clinical development, health economics, and commercialization strategy across biotech, specialty pharma, and consulting organizations. Proven record of shaping pipeline and asset strategy from early development through launch, building global and regional functions, guiding portfolio investment decisions, developing medical affairs strategies, engagement and deliverables, and securing payer and HTA success across major markets. Deep experience advising biotech leadership teams and boards on value creation, commercialization readiness, and investor strategy. Recognized experience in ophthalmology, rare disease, neuroscience, immunology, oncology, specialty care, and advanced therapies, with extensive experience across EU, US, and Asia-Pacific markets. Trusted advisor to executive teams and boards; experienced in building high-performance global teams and establishing scalable operating models for emerging and mid-sized biotech organizations.
Hobbies and Interests
- Golf
- Skiing (qualified instructor)
- Sailing
- Modern English literature
- Theatre
- Live music
Interests
- Active liveryman at the Worshipful Society of Apothecaries
- Founder Liveryman at the Company of Communicators
- Member of the Oxfordshire Golf Club and signature team player
- Member of England Golf Seniors
- Skiing and ski-coaching
Timeline
Head of Europe, Value Access & HTA
Neurocrine Biosciences
01.2023 - Current
Chairman of the Board
Biotherapy Services Ltd
01.2023 - Current
Chief Medical Affairs Officer & Global Head, WG Access
WPP Health / VMLY&R / WG Access
01.2018 - 01.2023
International Head, Value & Access
Allergan International (now AbbVie)
01.2013 - 01.2018
Global Director, Market Access
Novartis Pharma
01.2012 - 12.2012
Vice President & Senior Director, Consulting
PAREXEL International
01.2009 - 12.2012
Managing Director
WG Consulting (WPP)
01.2004 - 12.2009
PhD - Neuropharmacology
University of Manchester
BSc (Hons) - Pharmacology
University of Liverpool
Strategic Leadership Programme -
Chicago Booth School of Business
Health Economics Certificate -
Brunel University
TEFL -
Florence